Table 1:
Patient Characteristics by Study Arm*
| All patients | Intervention arm | Usual care arm | P values | |
|---|---|---|---|---|
| (N=718) | (N=349) | (N=369) | ||
| Age (mean (standard deviation)) | 77·2 (5·4) | 77·2 (5·7) | 77·2 (5·2) | 0·98 |
| 70–79 | 494 (68·8%) | 244 (69·9%) | 250 (67·8%) | 0·61 |
| 80–89 | 204 (28·4%) | 94 (26·9%) | 110 (29·8%) | |
| ≥90 | 18 (2·5%) | 10 (2·9%) | 8 (2·2%) | |
| Missing | 2 (0·3%) | 1 (0·3%) | 1 (0·3%) | |
| Gender | 0·35 | |||
| Male | 405 (56·4%) | 203 (58·2%) | 202 (54·7%) | |
| Female | 311 (43·3%) | 145 (41·5%) | 166 (45·0%) | |
| Missing | 2 (0·3%) | 1 (0·3%) | 1 (0·3%) | |
| Race/Ethnicity | <0·01 | |||
| Non-Hispanic White | 628 (87·5%) | 281 (80·5%) | 347 (94·0%) | |
| Black | 52 (7·2%) | 40 (11·5%) | 12 (3·3%) | |
| Others | 35 (4·9%) | 26 (7·4%) | 9 (2·4%) | |
| Missing | 3 (0·4%) | 2 (0·6%) | 1 (0·3%) | |
| Marital Status | 0·32 | |||
| Single, Never Married | 17 (2·4%) | 11 (3·2%) | 6 (1·6%) | |
| Married/ Domestic Partnership | 449 (62·5%) | 212 (60·7%) | 237 (64·2%) | |
| Separated/ Widowed/ Divorced | 250 (34·8%) | 125 (35·8%) | 125 (33·9%) | |
| Missing | 2 (0·3%) | 1 (0·3%) | 1 (0·3%) | |
| Education | 0·67 | |||
| <High school | 111 (15·5%) | 58 (16·6%) | 53 (14·4%) | |
| High school graduate | 244 (34·0%) | 119 (34·1%) | 125 (33·9%) | |
| Some college or above | 361 (50·3%) | 171 (49·0%) | 190 (51·5%) | |
| Missing | 2 (0·3%) | 1 (0·3%) | 1 (0·3%) | |
| Income | 0·16 | |||
| ≤$50,000 | 371 (51·7%) | 189 (54·2%) | 182 (49·3%) | |
| >$50,000 | 190 (26·5%) | 94 (26·9%) | 96 (26·0%) | |
| Decline to answer | 155 (21·6%) | 65 (18·6%) | 90 (24·4%) | |
| Missing | 2 (0·3%) | 1 (0·3%) | 1 (0·3%) | |
| Cancer type | <0·01 | |||
| Breast | 56 (7·8%) | 19 (5·4%) | 37 (10·0%) | |
| Gastrointestinal | 246 (34·2%) | 132 (38·0%) | 114 (30·8%) | |
| Genitourinary | 109 (15·2%) | 56 (16·0%) | 53 (14·4%) | |
| Gynecological | 43 (6·0%) | 29 (8·3%) | 14 (3·8%) | |
| Lung | 180 (25·1%) | 64 (18·3%) | 116 (31·4%) | |
| Lymphoma | 46 (6·4%) | 23 (6·6%) | 23 (6·2%) | |
| Other | 38 (5·3%) | 26 (7·4%) | 12 (3·3%) | |
| Cancer stage | 0·11 | |||
| Stage III | 77 (10·7%) | 42 (12·0%) | 35 (9·5%) | |
| Stage IV | 628 (87·5%) | 304 (87·1%) | 324 (87·8%) | |
| Others | 13 (1·8%) | 3 (0·9%) | 10 (2·7%) | |
| Prior chemotherapy | 185 (26·6%) | 104 (30·8%) | 81 (22·7%) | 0·02 |
| Number of Impaired Geriatric Assessment Domains** (mean (SD)) | 4·5(1·6) | 4·6(1·6) | 4·4(1·5) | 0·23 |
| Physical performance domain impairment | 669 (93·2%) | 314 (90·0%) | 355 (96·2%) | <0·01 |
| Polypharmacy domain impairment | 584 (81·3%) | 287 (82·2%) | 297 (80·5%) | 0·65 |
| Comorbidity domain impairment | 484 (67·5%) | 236 (67·6%) | 248 (67·4%) | 0·90 |
| Functional status domain impairment | 412 (57·5%) | 200 (57·3%) | 212 (57·6%) | 0·96 |
| Nutrition domain impairment | 439 (61·1%) | 211 (60·5%) | 228 (61·8%) | 0·71 |
| Cognition domain impairment | 261 (36·4%) | 140 (40·1%) | 121 (32·8%) | 0·04 |
| Social support domain impairment | 194 (27·1%) | 111 (31·8%) | 83 (22·6%) | <0·01 |
| Psychological status domain impairment | 205 (28·6%) | 107 (30·7%) | 98 (26·6%) | 0·22 |
*
Missing data for any variable <5%; p-values included since this is a cluster randomized trial
**
See Table 3 for Domain Definitions